Dose reductions with KISQALI mean no need for new mid-cycle prescriptions or additional costs

For patients with HR+/HER2- mBC,

• KISQALI is given as 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) with either¹:

  • An AI once daily (continuously); in men and premenopausal women, an LHRH agonist should also be administered according to current clinical practice guidelines; or 

  • Fulvestrant 500 mg intramuscularly on Days 1, 15, and 29, and once monthly thereafter; in men and premenopausal women, an LHRH agonist should also be administered according to current clinical practice guidelines

• Dose adjustments for adverse reactions should be made in a stepwise order by reducing the number of tablets taken¹

• Dose modification of KISQALI is recommended based on individual safety and tolerability¹

• If dose reduction below 200 mg/day is required, discontinue treatment¹

• KISQALI can be taken with or without food¹

Expert perspective on dosing and patient adherence in HR+/HER2- mBC

“…the single-tablet strength allows for simple dose adjustments, and to me, that is game changing.” —Nick McAndrew, MD

Dose adjustment guidance in HR+/HER2- mBC¹